

CORRECTION


# Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

Jesús Troya, Pablo Ryan, Esteban Ribera, Daniel Podzamczar, Victor Hontañón, Jose Alberto Terrón, Vicente Boix, Santiago Moreno, Pilar Barrufet, Manuel Castaño, Ana Carrero, María José Galindo, Ignacio Suárez-Lozano, Hernando Knobel, Miguel Raffo, Javier Solís, María Yllescas, Herminia Esteban, Juan González-García, Juan Berenguer, Arkaitz Imaz, GESIDA-8314 Study Group

The affiliation of the author Juan Berenguer is incorrect. The correct affiliation is: Hospital Universitario Gregorio Marañón, Madrid, Spain.

## Reference

1. Troya J, Ryan P, Ribera E, Podzamczar D, Hontañón V, Terrón JA, et al. (2016) Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS ONE 11(10): e0164455. doi: [10.1371/journal.pone.0164455](https://doi.org/10.1371/journal.pone.0164455) PMID: [27727331](https://pubmed.ncbi.nlm.nih.gov/27727331/)



## OPEN ACCESS

**Citation:** Troya J, Ryan P, Ribera E, Podzamczar D, Hontañón V, Terrón JA, et al. (2017) Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS ONE 12(2): e0172184. doi:10.1371/journal.pone.0172184

**Published:** February 9, 2017

**Copyright:** © 2017 Troya et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.